<DOC>
	<DOCNO>NCT01967576</DOCNO>
	<brief_summary>Background : - Most treatment malignant pheochromocytomas/paragangliomas ( PHEO/PGL ) palliative multidisciplinary . Chemotherapy use combination cyclophosphamide , vincristine , dacarbazine successfully utilized management rapidly progressive metastatic PHEO , 50 % complete partial tumor response 70 % complete partial biochemical response . - VEGF expression evidence angiogenesis find many PHEO/PGL , plausible interfere VEGF signaling may result anti-tumor activity patient PHEO/PGL . - Axitinib ( AG-013736 ) oral , potent selective inhibitor vascular endothelial growth factor ( VEGF ) receptors 1 , 2 , 3 . Pre-clinical data suggest anti-tumor activity axitinib may result anti-angiogenic activity reversible treatment discontinue . - Given known clinical safety efficacy axitinib , assessment activity PHEO/PGL impact VEGF pathway PHEO/PGL could provide valuable information . Objectives : - Determine response rate metastatic PHEO/PGL axitinib ( AG-013736 ) . - Determine progression-free survival metastatic PHEO/PGL treat axitinib ( AG-013736 ) . - Explore relationship potential biological marker axitinib activity clinical outcome . - Perform pharmacogenomics analyse drug metabolism transport proteins germline DNA examination . Eligibility : - Adults confirm pathologic diagnosis PHEO/PGL Laboratory Pathology , NCI - Biochemical evidence PHEO/PGL - Imaging confirmation metastatic , locally advance unresectable disease . - Measurable disease presentation - ECOG performance status less equal 2 - Patients must receive prior therapy tyrosine kinase ( TK ) inhibitor Design : - Phase II , open label , non-randomized trial - Patients metastatic pheochromocytoma/paraganglioma receive axitinib ( AG- 013736 BID ) eight-week cycle - Patients evaluate response every eight week use RECIST criterion - Tumor biopsy mandatory every attempt make obtain patient prior start axitinib 20 -30 day treatment begin . - Approximately 12 37 patient need achieve objective trial</brief_summary>
	<brief_title>Phase II Study Axitinib ( AG-013736 ) With Evaluation VEGF-pathway Metastatic , Recurrent Primary Unresectable Pheochromocytoma/Paraganglioma</brief_title>
	<detailed_description>Background : - Most treatment malignant pheochromocytomas/paragangliomas ( PHEO/PGL ) palliative multidisciplinary . Chemotherapy use combination cyclophosphamide , vincristine , dacarbazine successfully utilized management rapidly progressive metastatic PHEO , 50 % complete partial tumor response 70 % complete partial biochemical response . - VEGF expression evidence angiogenesis find many PHEO/PGL , plausible interfere VEGF signaling may result anti-tumor activity patient PHEO/PGL . - Axitinib ( AG-013736 ) oral , potent selective inhibitor vascular endothelial growth factor ( VEGF ) receptors 1 , 2 , 3 . Pre-clinical data suggest anti-tumor activity axitinib may result anti-angiogenic activity reversible treatment discontinue . - Given known clinical safety efficacy axitinib , assessment activity PHEO/PGL impact VEGF pathway PHEO/PGL could provide valuable information . Objectives : - Determine response rate metastatic PHEO/PGL axitinib ( AG-013736 ) . - Determine progression-free survival metastatic PHEO/PGL treat axitinib ( AG-013736 ) . - Explore relationship potential biological marker axitinib activity clinical outcome . - Perform pharmacogenomics analyse drug metabolism transport proteins germline DNA examination . Eligibility : - Adults confirm pathologic diagnosis PHEO/PGL Laboratory Pathology , NCI - Biochemical evidence PHEO/PGL - Imaging confirmation metastatic , locally advance unresectable disease . - Measurable disease presentation - ECOG performance status less equal 2 - Patients must receive prior therapy tyrosine kinase ( TK ) inhibitor Design : - Phase II , open label , non-randomized trial - Patients metastatic pheochromocytoma/paraganglioma receive axitinib ( AG-013736 BID ) eight-week cycle - Patients evaluate response every twelve week ( +/- 1 week ) use RECIST criterion - Approximately 12 37 patient need achieve objective trial</detailed_description>
	<mesh_term>Pheochromocytoma</mesh_term>
	<mesh_term>Paraganglioma</mesh_term>
	<mesh_term>Carotid Body Tumor</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>INCLUSION CRITERIA 2.1.1 Adults confirm pathologic diagnosis pheochromocytoma/paraganglioma Laboratory Pathology , NCI tissue available confirm In event outside tissue available : outside pathology report confirm diagnosis PheoPGI , AND patient nuclear medicine imaging study would positive adult patient diagnosis Pheo/PGL ( FDOPA , Dotatate , FDopamine MIBG ) 2.1.1.2 Imaging confirmation metastatic disease 2.1.1.3 Measurable disease time enrollment . 2.1.1.4 A life expectancy least 3 month ECOG performance status less equal 2 2.1.1.5 Age great equal 18 year 2.1.1.6 Information available pending regard possible genetic alteration explain patient pheochromocytoma/paraganglioma ( mutation SDHB , SDHV VHL gene ) 2.1.1.7 Last dose chemotherapy experimental therapy 4 week ( 6 week case nitrosourea ) prior enrollment date ; 2 week last therapy receive part phase 0 exploratory IND trial . Last surgery 4 week prior enrollment , allow wound heal . Core biopsy FNA require wait period 2.1.1.8 Last radiotherapy treatment great equal 4 week prior start treatment protocol must sit measurable disease receive radiation 2.1.1.9 Prior therapeutic MIBG allow 2.1.1.10 Organ marrow function define : 2.1.1.11 Total bilirubin less equal 1.5 x ULN ( upper limit normal ) , unless patient meet criteria Gilbert Syndrome . The upper limit value bilirubin subject Gilbert Syndrome le 3 mg/dl . Note : A diagnosis Gilbert disease make presence ( 1 ) unconjugated hyperbilirubinemia note several occasion ; ( 2 ) normal result CBC count , reticulocyte count , blood smear ; ( 3 ) normal liver function test result ; ( 4 ) absence disease process explain unconjugated hyperbilirubinemia . 2.1.1.12 AST less equal 2.5 x ULN , ALT le equal 2.5 x ULN 2.1.1.13 Amylase lipase equal , less , institutional ULN . 2.1.1.14 Creatinine clearance ( Bullet ) 40 ml/min ( estimate measure creatinine clearance ) serum creatinine 1.6 mg/dl Note : Random urine protein &lt; 20 mg/dL . If great equal 20 mg/dL 24hour urine protein collection perform accurately demonstrate 24hour total &lt; 1000 mg , level acceptable enrollment study 2.1.1.15 Absolute neutrophil count great equal 500/mm ( 3 ) 2.1.1.16 Platelet count great equal 50,000/ mm ( 3 ) 2.1.1.17 Ability understand sign inform consent document . 2.1.1.18 Ability willingness follow guideline clinical protocol include visit NICHD NCI , Bethesda , Maryland treatment follow visit . 2.1.1.19 Because effect chemotherapy develop human fetus potentially harmful , woman childbearing potential men participate study must agree use adequate contraception ( hormonal barrier method ) , study period 3 month last dose chemotherapy . EXCLUSIONCRITERIA 2.1.2.1 Patients pheochromocytoma/paraganglioma tumor potentially curable surgical excision alone determine Principal Investigator discussion surgical consultant 2.1.2.2 Patients large abdominal mass impinge bowel pulmonary mass encroach vessel potential bleed consider case case basis careful consultation multiple discipline radiologist surgeon main intent patient safety . 2.1.2.3 Unstable hypertension define systolic blood pressure &gt; 150 mm Hg diastolic pressure &gt; 90 mmHg despite optimal medical management . 2.1.2.4 Untreated brain metastasis ( local treatment brain metastasis within last 6 month ) due poor prognosis patient difficulty ascertain cause neurologic adverse event . 2.1.2.5 Pregnancy , due possible adverse effect develop fetus . 2.1.2.6 Lactating woman breastfeed due possibility transmit axitinib child . 2.1.2.7 The presence second malignancy , squamous cell carcinoma skin situ cervical cancer complicate primary objective study . Cancer survivor free disease least two year enrol study . 2.1.2.8 Patients evidence bleed diathesis 2.1.2.9 Patients must receive prior therapy TKI . Prior TKI usage pheochromocytoma affect pathway axitinib . 2.1.2.10 Gastrointestinal abnormality include : Inability take oral medication Requirement intravenous alimentation Prior surgical procedure affect absorption include total gastric resection Treatment active peptic ulcer disease past 6 month Active gastrointestinal bleeding , unrelated cancer , evidence hematemesis , hematochezia melena past 3 month without evidence resolution document endoscopy colonoscopy Malabsorption syndrome 2.1.2.11 Current use anticipate need treatment drug know potent CYP3A4 inhibitor ( i.e. , grapefruit juice , verapamil , ketoconazole , miconazole , itraconazole , erythromycin , telithromycin , clarithromycin , indinavir , saquinavir , ritonavir , nelfinavir , lopinavir , atazanavir , amprenavir , fosamprenavir , delavirdine ) . 2.1.2.12 Current use anticipate need treatment drug know CYP3A4 CYP1A2 inducer ( i.e. , carbamazepine , dexamethasone , felbamate , omeprazole , phenobarbital , phenytoin , amobarbital , nevirapine , primidone , rifabutin , rifampin , St. John wort ) . 2.1.2.13 Requirement anticoagulant therapy oral vitamin K antagonists . Lowdose anticoagulant maintenance patency central venous access device prevention deep venous thrombosis allow . Therapeutic use low molecular weight heparin allow . 2.1.2.14 Active seizure disorder evidence brain metastasis , spinal cord compression , carcinomatous meningitis . 2.1.2.15 Any follow within 12 month prior study drug administration : myocardial infarction , uncontrolled angina , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident transient ischemic attack within 6 month study drug administration deep vein thrombosis pulmonary embolism . 2.1.2.16 Other severe acute chronic medical psychiatric condition , laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 31, 2017</verification_date>
	<keyword>Mutation SDHB gene</keyword>
	<keyword>Mutation SDHV gene</keyword>
	<keyword>Mutation VHL gene</keyword>
	<keyword>Pharmacogenomics analysis</keyword>
	<keyword>Germline DNA examination</keyword>
</DOC>